AegirBio

"We are committed to advancing our capabilities and developing saliva based diagnosis as an alternative to blood tests for identifying systemic disease and other health issues," said Marco Witteveen. "This presentation highlights our strategic priorities and our roadmap for sustainable growth. However, achieving these goals is only possible with the continued support of our current and new investors to fund our progress moving forward."

The video is accessible to stakeholders, investors, and industry professionals who wish to gain a deeper understanding of Magnasense AB’s future plans. For more information, visit www.magnasense.com.